COVID-19 Response BioXplor's team and collaborators at Univeristy of Manitoba have structured over 100,000 COVID-19 related publications and analysed over 100,000 patient SARS-CoV-2 genomes for variants. These resources we understand to be one of the largest publicly available repositories of COVID-19 data.
We have developed an ontology-driven search engine and genome browser, and developed an evidence based approach to identify anti-inflammatory and anti-viral drug combinations by safety and efficacy.
SARS-CoV-2 Genome Browser
COVID-19 Intelligent Search Engine
COVID-19 R&D Discovery Platform
BioXplor has exposed part of it's biomedical knowledge platform to accelerate the discovery of actionable insights from the torrent of COVID-19 literature. The COVID-19 Discovery Engine is completely open-access and supported by COVID-19 response grants, programs & partnerships with EIT Health (European Innovation and Technology Institute), Creative Destruction Labs, and University of Manitoba /MITACS (Haigh Laboratory). The COVID-19 Discovery Engine is being integrated as part of a collaboration with a team of experts on a Royal Society of Chemistry book (in draft) 'Translational Toxicology of Antiviral Agents -- The COVID-19 Pandemic and the Future'.
The engine is one of most comprehensive resources for ontology-based knowledge discovery & text mining in COVID-19. It combines structured content from over 50,000 COVID-19 related full-text scientific papers from the CORD-19 dataset including PubMed, WHO, Elsevier, PubMed Central, BioRxiv, MedRxiv, using 30+ proprietary biomedical ontology dictionaries to enable scientists to discover insights up to 25X faster than Google Scholar or Pubmed.
Open Access Here
COVID-19 Literature Discovery Engine
Access Variant Data
SARS-CoV-2 Viral Variant Tracker & Primer Design Tool
BioXplor is collaborating with the University of Manitoba to develop and distribute a computational platform to track SARS-CoV-2 viral variants in different populations via sequencing data analysis. BioXplor is offering
partnerships to mRNA Vaccine developers and Molecular Diagnostics companies of NGS and RT-PCR test kits for optimal designs to avoid mutational hotspots. In the BioArxiv paper: "early mutational events are described across samples from publicly available SARS CoV-2 sequences from the sequence reads, mostly from China, USA (Washington DC) and Australia 30 (Victoria). 90% of datasets contain at least a single founder mutation and most of the variants are missense (over 63%). Five-point mutations with clonal (founder) effect were found in USA sequencing samples. Australian mutation signatures were more diverse than USA samples."
BioXplor's network immunopharmacology platform is being utilized to identify immunomodulation drug targets and drug combinations for COVID-19. The goal is to bring currently novel drug combinations to IND filing and subsequent clinical trials novel drug combinations with strong evidence of synergy, safety and efficacy for treatment of high-risk patients with severe disease in COVID-19.
Request More Information
Case Study - COVID-19 Drug Combinations